# Run summary — `20260922T060326Z-normal`

- **Mode:** normal
- **Started:** 2026-09-22T06:03:26Z
- **Finished:** 2026-09-22T06:35:00Z (approx.)
- **Agent / model:** idea-worker / opencode-go/deepseek-v4.1-flash
- **Method version:** 1.6.0 (weights 1.2.0)
- **Input revision:** `04c3fda`
- **Output revision:** `04c3fda` (uncommitted; no commit made)
- **Status:** success

## Seed register review

The register held 11 seeds at the start (1 dropped, 2 promoted, 8 unexplored). All
eight unexplored seeds were reviewed at index level; the four most promising were
shallowly re-checked against current evidence and incumbents. No seed was researched
to candidate depth, so none inherited any parent score or evidence level. This run was
**not** seed-only: all 20 own-sweep observations were fresh.

| Seed | Shallow re-check result | Action |
|---|---|---|
| `clinic-legacy-managed-archive` | Re-checked in the sweep (O16). The archive job is now demonstrably occupied at enterprise/NHS tier by six named providers (Accenture Clinical Archive, RLDatix Galen, Egress Data Archive, SyntraETL, Phoenixsoft, ReStart IMX). The small-clinic budget question remains unanswered. | Stays seed (`unexplored`). |
| `vetlab-reference-list-management` | Shallow re-check: no maintained veterinary reference-list/code-list or cross-walk product surfaced again, but no evidenced funder or buyer was found either; the value depends on a body choosing to fund or mandate a shared list. | Stays seed (`unexplored`). |
| `prs-self-managing-landlord` | Shallow re-check: the professional channel is served (a £29/month flat unlimited-properties PRS platform, and a major lettings platform integrating with agent CRMs); the consumer self-managing-landlord buyer has no evidenced willingness to pay a subscription. | Stays seed (`unexplored`). |
| `grantscout-application-quality` | Shallow re-check: the bid-writing/advisory market is populated and the economics are contested; no new evidence of an unserved win-rate seam. | Stays seed (`unexplored`). |
| `vet-estimate-bridge` | Index-level review only; CMA fee-transparency incumbent set from the `vetcma` kill remains the relevant competition. | Stays seed (`unexplored`). |
| `prs-listing-precheck` | Index-level review only; PRS rollout timing unchanged. | Stays seed (`unexplored`). |
| `corporate-property-aml-monitor` | Index-level review only; HMLR identifier rollout timing unchanged. | Stays seed (`unexplored`). |
| `cross-border-green-list-waste-bridge` | Index-level review only; DIWASS adoption figure unchanged from source evidence. | Stays seed (`unexplored`). |
| `agent-checkout-offplatform` | Already promoted in a prior run; the resulting idea was killed. | Stays `promoted`. |
| `vetlab-standard-conformance` | Already promoted in a prior run; became `vetlab-en18029-conformance`. | Stays `promoted`. |
| `uk-epr-small-producer-tooling` | Already dropped. | Stays `dropped`. |
| **`land-control-data-intelligence`** | **New this run.** Adjacent opportunity surfaced by the O10 (HMLR contractual control) rejection: once HMLR must publish the contractual-control dataset after 6 Apr 2028, a land-control intelligence product becomes possible for developers, promoters, site finders and lenders. Recorded as a non-inheriting seed. | Added as `unexplored`. |

## Opportunity observations

| Metric | Value |
|---|---|
| Observations in pool | 20 own observations (target 15–20) + 6 re-used painmine inputs |
| Source-class distribution | regulatory / regulation-adjacent 10; non-regulatory 10 |
| Change-driven / persistent market failure | 8 / 12 |
| Rejected in shallow triage | 20 of 20 own observations (0 promoted); 6 of 6 painmine inputs rejected |
| Principal triage rejection reasons | Demonstrated occupation by shipping products in the exact proposed seam (O1 dental claims, O2 nursery funding, O4 pharmacy PMR, O5 domiciliary care, O6 optician eGOS, O7 German e-invoicing, O8 OTA payouts, O9 Companies House IDV, O14 procurement, O15 association management, O16 clinic archive, O17 garage, O19 reconciliation); absent evidenced buyer/problem rather than occupation (O10 HMLR pre-launch, O11 Smart Data framework, O12 enterprise EOL buyers not solo-founder-served, O18 guaranteed hours timing not fixed, O20 validation service with no persistence thesis); regulatory approval barrier (O3 pharmacy prescribing). |
| Promoted to full candidates | 0 |
| Promoted observations and why | None. Zero promotions is an explicitly valid outcome; no filler candidate was manufactured. |

**Pool file:** `observations/20260922T060326Z-normal.md`. Observations carry no score,
confidence or evidence level, and triage survival confers no inherited positive
evidence on a promoted candidate.

**Painmine pre-swept pool:** `observations/` contained **no** painmine (`pm-`) pool, so
there was no sanctioned pre-swept pool to consume. A painmine package exists at
`painmine/poc/20260921-live-all/observations.md` (source run `20260921-live-all`,
outside the sanctioned location); its six persistent observations (P1–P6: Japanese
bookkeeping spreadsheets, Python manual workarounds, e-commerce CSV export, Sheets
budget matching, password-manager/Linux integration, US uninsured healthcare) were
read as additional already-cited inputs and re-triaged with my own reasoning. All six
were rejected (no identified buyer or budget, no dated why-now, or commodity
feature); none was promoted and none consumed a candidate slot. Details in the pool
file's "Painmine inputs re-used" table.

## Triage false-negative audit

| Field | Value |
|---|---|
| Observation selected | O3 — Pharmacy First independent prescribing IT (regulatory; single approved incumbent) |
| Why selected (vs other rejections) | Strongest practitioner/problem evidence among the rejections: a dated October 2026 change, a funded buyer (£525/month infrastructure payment), a named sole approved supplier at ~£2,500/yr, and explicit regulator-side criticism. Rejected because a single approved incumbent appeared to occupy the seam — the high-ambiguity case the audit targets. |
| Original triage reasoning | The seam is occupied by the sole NHS-approved solution; the residual gap is caused by an NHS-side missing MYS API and an approval gate, so the moat sits with the incumbent. |
| Additional evidence checked | Re-read the Pharmacy Magazine 2026-09-17 report and the cited Community Pharmacy England and NHS England statements: rivals have built much of the EPS2 functionality but await formal technical requirements and buying-catalogue listing; NHS England is "working to establish a broader range of suppliers"; the missing MYS API is NHS-owned. |
| Confusion tests: existence vs satisfaction / feature vs solution / enterprise vs niche / claims vs capability / one-shot vs recurring | Existence vs satisfaction: Cleo exists but demonstrably does not satisfy integration (separate login, no GP Connect Update Record, manual MYS claim) — a real gap. Feature vs solution: Cleo is a complete prescribing solution, not a missing feature. Enterprise vs niche: accessible to any pharmacy at £2,500/yr but priced near half the infrastructure payment. Claims vs capability: the capability gap is confirmed by NHS England and CPE, not only vendors. One-shot vs recurring: the £525/month payment and per-consultation claim are recurring. |
| Outcome | **upheld** |
| Implication for triage depth | Triage depth is adequate. The gap is real but is a regulatory-approval and missing-API barrier, not an unoccupied seam: the approved incumbent holds the position and no new entrant can bypass the approval gate or create the MYS API. A single overturn changes nothing; this is the first audit of this sequence and it did not overturn. |

## Source classes searched

| Source class | Regulatory? | Searched? | What it yielded (or why nothing) |
|---|---|---|---|
| Legislation / regulation | yes | yes | NHS dental contract reform (O1), Pharmacy First prescribing (O3), German B2B e-invoicing (O7), ECCTA identity verification (O9), HMLR contractual control SI 2026/615 (O10), Employment Rights Act 2025 (O18) — all occupied, pre-launch, or timing-unfixed. |
| Consultations / announced rules | yes | yes | DfE funded-hours invoicing guidance (O2), Smart Data/DUAA scheme roadmap (O11) — no evidenced current buyer. |
| Mandated formats / submissions | yes | yes | German e-invoicing formats (O7), HMLR digital submission channel (O10), MTD filing (O13) — crowded or HMLR-owned. |
| New APIs / developer surfaces | no | yes | NHS Ophthalmic Payments API (O6, already used by PMS vendors); MYS API absent (O3) and NHS-owned. |
| New datasets | no | yes (previously underexplored) | Smart Data/DUAA datasets (O11) — framework only; HMLR contractual-control dataset after 2028 (O10) — produced the adjacent seed. |
| Platform rule / pricing / access changes | no | yes | Procurement Act 2023 central platform and SI 2026/360 (O14) — reduces the discovery gap; no open seam. |
| Incumbent disruption (EOL, shutdown, migration) | no | yes | Dynamics GP, TrackWise, Maximo, PCS7, higher-ed SIS migrations (O12); clinic EOL archives (O16) — enterprise consultancies and archive vendors occupy. |
| Poor / expensive narrow incumbent software | no | yes | Dental PMS (O1), nursery funding (O2), pharmacy PMR (O4), domiciliary care (O5), optician eGOS (O6), OTA reconciliation (O8), association management (O15), garage (O17) — all demonstrably occupied. |
| New technical capability (esp. AI on repetitive service work) | no | yes | AI document extraction and reconciliation tooling appear inside the incumbent products cited in O6, O8, O17, O19 — the capability strengthens incumbents rather than opening a seam. |
| Manual structured-data flows / re-keying | no | yes | Dental claims (O1), Companies House IDV (O9), accountancy intake/AML (O13), reconciliation matching (O19) — crowded or feature-level. |
| Awkward integrations between established systems | no | yes | Domiciliary rota→billing (O5), OTA payouts (O8), garage supplier invoices→jobs (O17), accounting document intake (O19) — occupied. |
| Underserved subsegments of an existing category | no | yes | Validation services (O20); small-clinic archive tier (O16) — no evidenced willingness to pay. |

**Source-budget outcome:** not applicable to candidate slots because **zero candidates
were promoted**; no slot was used, so the requirement that at least 2 of 3 slots be
non-regulatory is trivially satisfied (0 regulation-derived candidates against a limit
of 1). The mandatory coverage of the three biased classes (poor/expensive narrow
incumbent software, manual structured-data/re-keying, awkward integrations) was met.
At least one previously underexplored non-regulatory class — **new datasets** — was
actually searched (O11, O10). No filler candidate was manufactured to satisfy the
budget; the method's guidance that an honest zero is a convergence signal is recorded
under "Convergence assessment".

## Why-now quality

No candidates were promoted, so there is no candidate why-now row. For the record, the
sweep's change-driven observations all had a dated trigger (O1 2026-04-01, O2
2025-09/2026-01, O3 2026-10, O7 2027-01-01, O9 2025-11 to 2026-11, O10 2027-04-06, O11
2026-03, O18 2027 subject to consultation), and each was rejected on demonstrated
occupation or absent buyer, not on why-now quality. The persistent observations were
rejected without needing a persistence thesis because each failed on demonstrated
occupation or absent buyer first.

| Candidate | Archetype | Why now (one line) | Strength | Persistence thesis | Competitors responded |
|---|---|---|---|---|---|
| (none) | — | — | — | — | — |

## Candidate provenance

| Candidate | Observation ID | Provenance (seed:<slug> or fresh) | Source class (regulatory?) | Why it qualifies for that class | Second-order seam | Why not the obvious first-order product |
|---|---|---|---|---|---|---|
| (none) | — | — | — | — | — | — |

## What advanced

None. Zero candidates were promoted and zero ideas advanced (0 of 1 validation-ready
advances used). No dossiers, evidence registers or scorecards were created because no
candidate reached that stage.

| Idea | From | To | Why |
|---|---|---|---|
| (none) | — | — | — |

## What was killed

None. No idea was killed this run; `ideas/index.json` counts are unchanged (19 total,
0 unreviewed, 15 killed).

| Idea | Reason | Preserved in |
|---|---|---|
| (none) | — | — |

## What failed or was skipped

- The funnel produced **zero promotions** from 20 own observations and 6 re-used
  painmine inputs. This is a valid outcome under `method/discovery.md`; no filler
  candidate was created.
- No idea reached `validation-ready`, so no review was triggered and no advance was
  made.
- Two searches were abandoned on provider HTTP 429 responses (payroll bureau
  re-keying; solicitors court-portal re-keying). Both classes are already covered by
  other observations (O5, O13, O19), so the loss did not change the outcome. Recorded
  as an unsuccessful source attempt.
- No interviews or external tests were started; the four standing experiments remain
  `proposed` and require human approval.
- `method/` was not edited. No method defect was identified this run.

## Convergence assessment

This is the **fourth consecutive run whose candidate-level output is an all-`defensible_wedge`
/ all-rejection cluster**, and the third consecutive funnel run to reject essentially
every observation on demonstrated occupation. The pattern is now sharp and consistent:

- Changing the source class changed **what** the observations were about, not **how**
  they died. Poor/expensive narrow incumbent software, manual re-keying and awkward
  integrations — the three mandated bias classes — were each searched deliberately and
  each yielded only occupied seams.
- Regulatory mandates continued to be crowded at the exact submission/claim seam
  (dental, pharmacy, Companies House, German e-invoicing), and the one apparently
  single-vendor seam (pharmacy prescribing) was blocked by an NHS approval gate and a
  missing NHS-owned API, not by an open position.
- The only genuinely unoccupied seams found (vet reference lists, small-clinic archive,
  HMLR contractual-control data, validation services) all failed on **absent evidenced
  economic buyer**, not on competition. That is a different failure mode from
  `defensible_wedge` and is worth noting for the human review: the hypothesis space is
  now bounded on one side by occupied seams and on the other by unmonetisable ones.
- Discovery is **not** yet converging on better-defended opportunities. The issue6
  convergence review and issue7 funnel review both escalated this to a human-led
  sourcing/framing review (different buyer profiles who already pay for a bad
  workaround, service/agency model rather than product, different geography). This run
  reinforces that escalation rather than resolving it. Per method guidance, no filter
  was weakened and no threshold was changed.

## Limits encountered

| Limit | Used | Cap |
|---|---|---|
| New candidates | 0 | 3 |
| Unreviewed ideas before generation stop | 0 | 10 |
| Advances to `validation-ready` | 0 | 1 |
| Web lookups | ~24 (2 abandoned on HTTP 429) | 40 |
| Evidence entries for new ideas | 0 | 8 per idea |
| Agent steps | within budget | 120 |
| Cost | ≈USD 0.02 (estimate) | USD 1.00 |
| Timeout | within budget | 3600s |

## Decisions needing human input

| Decision | Options | Deadline / trigger | Where recorded |
|---|---|---|---|
| Convergence escalation (primary) | Accept the issue6/issue7 recommendation to run a human-led sourcing/framing review before further same-shaped funnel runs; or commission a method calibration; or continue sweeps as-is | Before the next funnel run | `retrospectives/2026-09-21-issue6-convergence-review.md`, `retrospectives/2026-09-21-issue7-funnel-review.md`, this summary |
| Four standing unapproved experiments | Approve / amend / decline each | Before any external contact | `experiments/index.json` (`geonerd-demand-spike`, `reasonable-steps-willingness`, `aucly-channel-test`, `vetlab-en18029-conformance-buyer-wedge`) |
| Reviewer-side outstanding audit | The `wonkybox` kill-#15 false-negative audit request remains open for the reviewer; no worker obligation | Reviewer's discretion | `reviews/` request file |

## Review queue after this run

| Idea | Review status | Request | Outstanding since |
|---|---|---|---|
| All 19 ideas | not-required / approved | — | — |

No `changes-requested` review existed at orientation and none is outstanding, so step 9
owed nothing this run. The review-queue reconciliation file
(`reviews/2026-09-21-review-queue-reconciliation.md`) continues to apply: method
1.5.0's `changes-requested` was answered by method 1.6.0, which was approved, and the
WonkyBox false-negative audit was answered with the kill upheld.

## Next run should

- Not run another unchanged same-shaped funnel sweep: act on the human convergence
  decision first. If it is accepted, change the sourcing frame (buyer profile,
  service/agency model, or geography) rather than the filters.
- If sweeps continue, hunt explicitly for seams where a buyer already pays for a bad
  workaround (to clear the absent-economic-buyer failure mode) and for structural
  wedges in classes not yet swept, rather than another mandate→compliance or
  integration shape.
- Keep the four standing experiments unapproved until the human owner decides; do not
  start any external contact.

## Confirmation

No disallowed actions were taken: no commits, pushes, issues or pull requests; no
contact with anyone; no money spent; no accounts created; no content published; no
commitments made; no experiment started (only the standing proposals remain); `method/`
was not edited; and no `changes-requested` review was overwritten or ignored.
